Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 27 Oct 2026

Dr. Reddy’s Laboratories reported a 36% year-on-year decline in profit attributable to equity holders at ₹925 crore in Q2 FY27, as lower lenalidomide sales weighed on its North American business.

4 publishers have reported this development. Each act of reporting is below, cited.

The record

Dr. Reddy’s Laboratories reported a 36% year-on-year decline in profit attributable to equity holders at ₹925 crore in Q2 FY27, as lower lenalidomide sales weighed on its North American business.

businesstoday.in27 Oct 2026

Dr. Reddy’s Laboratories reported a strong margin recovery in its second quarter results on Friday.

Dr. Reddy's announced for the second quarter of FY2027 its revenue fell 1.5% to ₹8,671 crore while the profit after tax fell 36% to ₹925 crore versus ₹1,437 crore in the previous year.

indiatimes.com24 Oct 2026

Dr Reddy’s Laboratories’ net profit declined 36 per cent to ₹925 crore in the second quarter ended September 2026.

Dr. Reddy’s Laboratories reported a 36% year-on-year decline in second-quarter net profit to Rs 925 crore.

moneycontrol.com23 Oct 2026

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.